Anbio Biotechnology (NNNN) Return on equity 2022–2025
Anbio Biotechnology (NNNN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
21.2%FY2025 · since FY2022: 79.8% → 21.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 21.2% | +7.4 pp |
| FY2024 | 13.8% | -1.4 pp |
| FY2023 | 15.2% | -64.6 pp |
| FY2022 | 79.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Net marginNNNN Gross profitNNNN Gross marginNNNN Operating incomeNNNN Operating marginNNNN Operating cash flowNNNN Free cash flowNNNN Capital expendituresNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Total liabilitiesNNNN Shareholders’ equityNNNN overview →